Home
overview
The Aims & Objectives of the Conference

The occurrence of allergies is on the increase especially in industrialised societies. Moreover there is evidence that individuals are showing a progression of allergic symptoms. Consequently, pharmaceutical companies are investing increasing amounts into this rapidly developing area.

SMi’s conference, Recent Advances in the Prevention and Treatment of Allergy will focus on diagnostics, minimising allergenicity and new concepts in treatment. Regarding treatments, experts in the field will talk and lead discussions on CpGs, anti-leukotrienes, histamine antagonists, DNA-based immunotherapeutics and allergy vaccines. Furthermore there will be case studies and reports on specific new products from leading companies. This event aims to give you an excellent opportunity to learn about new developments in this exciting, fast-moving field, and provide you with excellent networking opportunities with leading experts from the Pharma industry.

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Dr Oliver Cromwell

Dr Oliver Cromwell, Head, Research & Development, Allergopharma

9:10 OVERVIEW

Stephen Lewington

Stephen Lewington, Vice President, Respiratory Disease, Global Marketing & Medical, Aventis

  • Patient, physician and payer perspectives
  • New developments in asthma and allergy treatments
  • Hurdles to success
  • Strategic partnering
  • 9:40 DIAGNOSTICS - I

  • Clinical expectations of the IgE antibody results
  • Understanding the IgE antibody response – Allergy March
  • Advantages of a quantitative IgE antibody test over a qualitative IgE antibody test
  • Requirements of a good test: allergen, calibration, validation
  • Performances of tests
  • WHO recommendations on diagnosis and treatment
  • Professor Staffan Ahlstedt

    Professor Staffan Ahlstedt, Director, Scientific Affairs, Pharmacia Diagnostics

    10:20 DIAGNOSTICS - II

    Dr Debra Burns

    Dr Debra Burns, Director, Project Support, Allergy and Infectious Disease Department, Diagnostic Products

  • Principles of immunoassays
  • Revolutionary aspects of Immulite 2000
  • Advantages over conventional methods
  • Cost and time savings
  • Ease of use

    Reliability

  • Flexibility
  • 11:00 Morning Coffee

    11:20 STRATEGIES IN ALLERGY BIOLOGICS AND BIOPHARMACEUTICS

    Dr Jan Willem Dorpema

    Dr Jan Willem Dorpema, General Director, HAL Allergy

  • Specific aspects of allergen products: cross reactivity, skin testing, standardisation, named patient products
  • Assessment of allergen products as biologics
  • Allergen products as active substances
  • Allergy vaccines: the first strike approach
  • Intra- and inter-cellular substances as biopharmaceutical drugs
  • Total managed care for allergy
  • 12:00 ALLERGENS

    Dr Anna Pomés

    Dr Anna Pomés, Research Director, INDOOR Biotechnologies

  • Allergenicity – intrinsic properties of allergens
  • Allergenicity – environmental factors
  • Allergens for research
  • Allergens for diagnosis
  • Allergens for treatment
  • Future possibilities
  • 12:40 Lunch

    14:00 ANTI-HISTAMINE

    Dr Serge Kouzan

    Dr Serge Kouzan, Head, Development Therapeutic Group, Allergy, Respiratory Disease, UCB Pharma

  • Prophylaxis for asthma
  • Mode of action
  • Selection of recipients
  • Duration and dose
  • Results of studies
  • Future benefits
  • 14:40 ANTI-LEUKOTRIENES AND ALLERGY

    Dr Jilly Evans

    Dr Jilly Evans, Director, Pharmacology, Merck

  • Singulair as an effective asthma controller
  • Singulair: potential for the treatment of allergic rhinitis
  • 15:20 COW’S MILK ALLERGY: MANAGEMENT AND PREVENTION

    Dr Roberto Moran

    Dr Roberto Moran, Vice President, Global Medical Affairs, Mead Johnson Nutritionals

  • Management: avoidance vs. immunologically recognised proteins
  • Prevention: new clinical evidence – the GINI trial in Europe
  • Probiotics – new paradigms?
  • 16:20 Chairman's Closing Remarks and Close of Day One followed by Afternoon Tea

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Professor Stephen Holgate

    Professor Stephen Holgate, MRC Professor, Immunopharmacology, University of Southampton

    9:10 HISTAMINE ANTAGONISTS

    Dr Heribert Staudinger

    Dr Heribert Staudinger, Vice President, Allergy Respiratory Disease, Schering Plough

  • Mode of action
  • Success with allergic rhinitis and asthma
  • Future development of antihistamines
  • Limitations of antihistamines
  • Advantages of combination with a leukotriene inhibitor: scientific support
  • Advantages of combination with a leukotriene inhibitor: medical support
  • 9:40 NON-STEROID APPROACH

    Professor Anton Stütz

    Professor Anton Stütz, Head, Inflammatory Skin Diseases, Novartis

  • Mode of action as a selective cytokine inhibitor
  • Advantages over corticosteroid treatment
  • Improvements in babies, children and adults
  • Results of clinical trials
  • Low incidence of side effects
  • Future possibilities
  • 10:20 ALLERGY VACCINATION

    Dr Lars Jacobsen

    Dr Lars Jacobsen, Head, Medical Communication & Clinical Relations, ALK-Abello

  • Identification and characterisation of allergen
  • Allergen sensitisation
  • Allergen reaction with IgE
  • Allergen reaction with specific T lymphocytes
  • Implication of allergen variance for sensitisation and treatment
  • Use of recombinant techniques for improving efficacy and safety
  • 11:00 Morning Coffee

    11:20 IMMUNOTHERAPY

    Professor Lars Hellman

    Professor Lars Hellman, Chief Scientific Officer, Resistentia Pharmaceuticals

  • Prevention of the emergence of allergy
  • Mode of action
  • Types of allergy which benefit
  • Development
  • Outlook for the future
  • 12:00 REDUCING ALLERGENICITY BY T CELL EPITOPE INACTIVATION

    Dr Fiona Harding

    Dr Fiona Harding, Staff Scientist, Genencor International

  • In vitro determination of allergenic protein components
  • Reengineering of functional, hypoallergenic proteins
  • Application to human health care
  • Application to personal care products
  • 12:40 Lunch

    14:00 CPGS

  • Immune modulation using CpG oligonucleotides
  • Ability of CpG ODN to shift a Th2 to a Th1 response
  • CpGs and prevention of remodelling in asthma
  • CpGs and treatment of established asthma
  • CpGs and rhinitis, atopic dermatitis
  • Outlook for the future
  • Professor Joel Kline

    Professor Joel Kline, Consultant, Coley Pharmaceutical Group

    14:40 IMMUNOTHERAPY WITH IMMUNOSTIMULATORY DNA SEQUENCES (ISS)

    Dr Robert Coffman

    Dr Robert Coffman, Vice President, Chief Scientific Officer, Dynavax

  • Basic properties of ISS-allergen conjugates
  • Specific allergen immunotherapy with ISS-allergen conjugates: clinical development
  • Specific allergen immunotherapy with ISS-allergen conjugates: mechanistic studies
  • Immune modulation in asthma with ISS-ODN alone
  • Implications for future treatment of allergic disease
  • 15:20 Afternoon Tea

    15:40 PEPTIDE IMMUNOTHERAPY

  • Nature of desensitising agent
  • Minimizing B cell epitopes
  • Advantages over conventional immunotherapy
  • Avoidance of side effects
  • Early clinical trials
  • Future outlook
  • Dr Mark Larché

    Dr Mark Larché, Consultant, Circassia/PowderJect

    16:20 NOTCH LIGAND SIGNALLING IN ALLERGY REGULATION

    Dr Brian Champion

    Dr Brian Champion, Vice President, Research, Lorantis

  • Immune regulation
  • Antigen-specific tolerance
  • Regulatory T cells
  • Immunomodulation by notch ligands
  • Implications for allergies to defined antigens
  • Future strategies
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.